McKesson stock gains support as RBC and Evercore stick with high targets
Published on 09/16/2026 at 13:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
McKesson Corporation stock (ISIN US58155Q1031) is drawing attention after fresh analyst updates kept ambitious price targets in place, with RBC Capital reaffirming a Hold rating and a USD 845.00 target on September 16, 2026, while Evercore maintained a Buy rating and a USD 1,000.00 target a day earlier. As of September 15, 2026, the stock was quoted around USD 899.56 on the New York Stock Exchange, underscoring how closely the current price already approaches these targets.
Analysts stick with elevated targets
According to The Globe and Mail on September 16, 2026, RBC Capital analyst Ryan Halsted reaffirmed a Hold rating on McKesson and set a price target of USD 845.00 per share, highlighting a consensus target of USD 987.75 across covering analysts. This places the RBC view modestly below the broader consensus, creating a benchmark that investors can weigh against the current share price level.
As Futunn News reported on September 15, 2026, Evercore analyst Elizabeth Anderson kept a Buy rating on McKesson and maintained a price target of USD 1,000.00 per share, signaling confidence in further upside beyond both the RBC target and the current market price. With consensus targets around USD 987.75, the Evercore view sits slightly above the average, suggesting that some houses still see the potential for the stock to move into four-digit territory.
Performance and valuation context
In terms of long-term performance, McKesson has delivered significant value to shareholders. According to Benzinga on September 15, 2026, McKesson generated an average annual return of 34.83% over the past five years, outperforming the market by 23.05 percentage points per year. The article illustrates this with a concrete example: a USD 100 investment five years ago would be worth USD 433.00 today, based on a share price of USD 899.56 at the time of writing.
This performance backdrop helps frame the current valuation discussion. With the shares around USD 899.56 and consensus targets near USD 987.75, the implied upside from the present level to the consensus is roughly 9.8%, while the gap to the Evercore target of USD 1,000.00 is about 11.2%. For investors, these numbers show that a substantial part of the long-term rerating has already occurred, yet analysts still see room for additional gains if the company continues to deliver.
Guidance and earnings expectations
Fundamental expectations also reinforce the analyst stance. As Simply Wall St discussed on September 15, 2026, McKesson recently raised its full-year earnings per share guidance, now pointing to expected EPS growth of approximately 13% to 15% on a reported basis and about 15% to 17% when excluding certain prior-year items. The same analysis projects revenue of about USD 502.2 billion and earnings of around USD 6.3 billion by 2029, which would imply annual revenue growth of 6.9% and an earnings increase of roughly USD 1.7 billion from about USD 4.6 billion currently.
These figures show that the positive rating from Evercore and the sustained consensus targets are underpinned by concrete growth expectations over the coming years. The raised EPS guidance suggests that management sees momentum in the underlying business, while the long-term projections from Simply Wall St outline how incremental growth in revenue and earnings could justify the current valuation and higher price targets if delivered.
Risks and insider activity
Alongside the bullish scenarios, investors need to consider risks and governance signals. Recent regulatory filings indicate active equity transactions by senior management. According to StockTitan, a Form 4 filing dated September 2, 2026, showed that Executive Vice President and Chief Legal Officer Michele Lau acquired 3,990 shares via restricted stock unit vesting and disposed of 1,421 shares at USD 962.32 per share to cover taxes, leaving 5,816 shares held directly after the transaction. While such transactions are largely routine, they nonetheless offer transparency on insider exposure at price levels above the recent USD 899.56 quote.
From a risk perspective, the Simply Wall St analysis also flags valuation and execution considerations. The site notes that, based on its fair value modeling, McKesson might currently trade with roughly an 8% potential upside to estimated fair value, suggesting that large parts of the upside implied by some long-term scenarios could already be reflected. In addition, any slowdown in the expected 6.9% annual revenue growth or a failure to achieve the projected increase in earnings from USD 4.6 billion to USD 6.3 billion by 2029 would challenge the more optimistic targets.
Stock level and investor takeaway
As of September 15, 2026, McKesson stock closed around USD 899.56 on the New York Stock Exchange, with the level sitting between the RBC Capital target of USD 845.00 and the Evercore target of USD 1,000.00. This positioning means the shares are trading above one major house's valuation mark while still below another's, leaving a moderate potential upside relative to the higher target and consensus. For investors, the combination of strong five-year returns, raised EPS guidance, and persistent high analyst targets suggests that McKesson remains a core healthcare holding where future performance will be judged against already demanding expectations.
McKesson stock key data
- Company: McKesson Corporation
- ISIN: US58155Q1031
- Ticker: MCK
- Trading venue: New York Stock Exchange
- Price (as of September 15, 2026): 899.56 USD
- Market capitalization: 43,300,000,000 USD (as of September 15, 2026, based on Benzinga example value)
- Sector / Industry: Health Care / Health Care Providers and Services
- Index membership: S&P 500
